PAT 1251

Drug Profile

PAT 1251

Alternative Names: PAT-1251

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAkea Therapeutics
  • Class Antifibrotics; Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis
  • Preclinical Hepatic fibrosis

Most Recent Events

  • 20 Oct 2017 Preclinical trials in Hepatic fibrosis in USA (PO)
  • 20 Oct 2017 Pharmacodynamics data from a preclinical trial in Hepatic fibrosis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 22 Aug 2017 PharmAkea completes the phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top